Literature DB >> 16831972

Axonal polyneuropathy after acute dimethylamine borane intoxication.

Hung-Chou Kuo1, Chin-Chang Huang, Chun-Che Chu, Nai-Shin Chu.   

Abstract

OBJECTIVE: To study a patient with axonal polyneuropathy due to acute dimethylamine borane (DMAB) intoxication. PATIENT: Confusion and drowsiness in the acute stage, followed by cognitive impairments and polyneuropathy, are reported in a chemical factory worker after acute exposure to DMAB.
RESULTS: Nerve conduction studies indicated axonal polyneuropathy, particularly in the motor nerves. Sural nerve biopsy studies 3 months later revealed an axonal degeneration with a mild decrease of fiber density in the large myelinated fibers. Quantitative sensory testing also disclosed an impairment of pinprick, temperature, and touch sensations. Cutaneous nerve biopsy studies 9 months later demonstrated a moderate loss of epidermal nerves. During the follow-up period of 1.5 years, the clinical features and serial nerve conduction studies showed a steady improvement.
CONCLUSIONS: Since DMAB is a new product and has been widely used recently in the manufacturing of semiconductors and electronics, we conclude that DMAB intoxication may produce motor-predominant axonal polyneuropathy and that the establishment of a threshold limit value is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831972     DOI: 10.1001/archneur.63.7.1009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  3 in total

1.  Occupational neurotoxic diseases in taiwan.

Authors:  Chi-Hung Liu; Chu-Yun Huang; Chin-Chang Huang
Journal:  Saf Health Work       Date:  2012-11-30

2.  Correspondence: Dimethylamine Borane Neurotoxicity and Authors' Response.

Authors:  Chin-Chang Huang; Hung-Chou Kuo; Yu-Tse Tsan; Dong-Zong Hung
Journal:  Environ Health Perspect       Date:  2006-05       Impact factor: 9.031

3.  Dimethylamine borane neurotoxicity.

Authors:  Chin-Chang Huang; Hung-Chou Kuo
Journal:  Environ Health Perspect       Date:  2006-05       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.